A decade-long observational follow-up reported that vagus nerve stimulation (VNS) was feasible and safe in nine implanted patients with Crohn’s disease, with sustained remission documented in three individuals on VNS alone. The report also reiterates that efficacy remains unproven given the small cohort and non-randomized design. The finding matters for device-based immunomodulation because it provides longer-term tolerability data than earlier short-term studies typically offer. However, the durability signals will likely need confirmation in controlled trials with objective endpoints and standardized definitions of remission. For clinicians and device developers, the key takeaway is that long-term implant safety can support future study designs—even as regulators and payers will still require higher-quality evidence for clinical benefit. —